A phase 1b study of lenvatinib plus pembrolizumab in unresectable hepatocellular carcinoma

被引：0

作者：

Finn, Richard ^{[1
]}

Ikeda, Masafumi ^{[2
]}

Zhu, Andrew ^{[3
,4
]}

Sung, Max W. ^{[5
]}

Baron, Ari D. ^{[6
]}

Kudo, Masatoshi ^{[7
]}

Okusaka, Takuji ^{[8
]}

Kobayashi, Masahiro ^{[9
]}

Kumada, Hiromitsu ^{[9
]}

Kaneko, Shuichi ^{[10
]}

Pracht, Marc ^{[11
]}

Mamontov, Konstantin ^{[12
]}

Meyer, Tim ^{[13
]}

Mody, Kalgi ^{[14
]}

Kubota, Tomoki ^{[15
]}

Dutcus, Corina E. ^{[14
]}

Saito, Kenichi ^{[14
]}

Siegel, Abby B. ^{[16
]}

Dubrovsky, Leonid ^{[16
]}

Llovet, Josep M. ^{[17
]}

机构：

[1] Univ Calif Los Angeles, Med Ctr, David Geffen Sch Med, Los Angeles, CA 90024 USA

[2] Nat Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[3] Massachusetts Gen Hosp, Boston, MA 02114 USA

[4] Jiahui Int Canc Ctr, Boston, MA USA

[5] Mt Sinai, Tisch Canc Inst, New York, NY USA

[6] Calif Pacific Med Ctr Res Inst, Sutter Hlth, San Francisco, CA USA

[7] Kindai Univ, Fac Med, Osaka, Japan

[8] Natl Canc Ctr, Tokyo, Japan

[9] Toranomon Gen Hosp, Tokyo, Japan

[10] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Kanazawa, Ishikawa, Japan

[11] Ctr Eugene Marquis, Rennes, France

[12] Altay Reg Oncol Hosp, Barnaul, Russia

[13] Royal Free London NHS Fdn Trust, London, England

[14] Eisai Inc, Woodcliff Lake, NJ USA

[15] Eisai & Co Ltd, Tokyo, Japan

[16] Merck & Co Inc, Kenilworth, NJ USA

[17] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

来源：

JOURNAL OF HEPATOLOGY | 2020年 / 73卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

LBO09

引用

页码：S120 / S121

页数：2

共 50 条

[1] A phase 1b trial of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma
Ikeda, Masafumi
Sung, Max W.
Kudo, Masatoshi
Kobayashi, Masahiro
Baron, Ari D.
Finn, Richard S.
Kaneko, Shuichi
Zhu, Andrew X.
Kubota, Tomoki
Kraljevic, Silvija
Ishikawa, Kohei
Siegel, Abby B.
Kumada, Hiromitsu
Young, Louise
Okusaka, Takuji
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 105 - 105
[2] A Phase 1b trial of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma
Ikeda, M.
Sung, M. W.
Kudo, M.
Kobayashi, M.
Baron, A. D.
Finn, R. S.
Kaneko, S.
Zhu, A. X.
Kubota, T.
Kraljevic, S.
Ishikawa, K.
Siegel, A. B.
Kumada, H.
Okusaka, T.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 37 - 37
[3] A Phase 1b Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116
Kudo, Masatoshi
Finn, Richard S.
Ikeda, Masafumi
Sung, Max W.
Baron, Ari D.
Okusaka, Takuji
Kobayashi, Masahiro
Kumada, Hiromitsu
Kaneko, Shuichi
Pracht, Marc
Meyer, Tim
Nagao, Satoshi
Saito, Kenichi
Mody, Kalgi
Ramji, Zahra
Dubrovsky, Leonid
Llovet, Josep M.
LIVER CANCER, 2024, 13 (04)
[4] A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
Llovet, Josep
Finn, Richard
Ikeda, Masfumi
Sung, Max
Baron, Ari
Kudo, Masatoshi
Okusaka, Takuji
Kobayashi, Masahiro
Kumada, Hiromitsu
Kaneko, Suichi
Pracht, Marc
Mamontov, Konstantin
Meyer, Tim
Mody, Kalgi
Kubota, Tomoki
Dutcus, Corina
Saito, Kenichi
Siegel, Abby
Dubrovsky, Leonid
Young, Louise
Zhu, Andrew X.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 189 - 190
[5] A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
Ikeda, Masafumi
Sung, Max W.
Kudo, Masatoshi
Kobayashi, Masahiro
Baron, Ari David
Finn, Richard S.
Kaneko, Shuichi
Zhu, Andrew X.
Kubota, Tomoki
Kraljevic, Silvija
Ishikawa, Kohei
Siegel, Abby B.
Kumada, Hiromitsu
Okusaka, Takuji
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[6] Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
Finn, Richard S.
Ikeda, Masafumi
Zhu, Andrew X.
Sung, Max W.
Baron, Ari D.
Kudo, Masatoshi
Okusaka, Takuji
Kobayashi, Masahiro
Kumada, Hiromitsu
Kaneko, Shuichi
Pracht, Marc
Mamontov, Konstantin
Meyer, Tim
Kubota, Tomoki
Dutcus, Corina E.
Saito, Kenichi
Siegel, Abby B.
Dubrovsky, Leonid
Mody, Kalgi
Llovet, Josep M.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (26) : 2960 - +
[7] Exploratory circulating biomarker analyses: lenvatinib plus pembrolizumab (L plus P) in a phase 1b trial in unresectable hepatocellular carcinoma (uHCC).
Zhu, Andrew X.
Llovet, Josep M.
Kobayashi, Masahiro
Ikeda, Masafumi
Pracht, Marc
Sung, Max W.
Baron, Ari David
Kudo, Masatoshi
Meyer, Tim
Okusaka, Takuji
Kumada, Hiromitsu
Kaneko, Shuichi
Hoshi, Taisuke
Saito, Kenichi
Li, Shuyu D.
Funahashi, Yasuhiro
Minoshima, Yukinori
Dubrovsky, Leonid
Finn, Richard S.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[8] A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).
Zhu, Andrew X.
Finn, Richard S.
Ikeda, Masafumi
Sung, Max W.
Baron, Ari David
Kudo, Masatoshi
Okusaka, Takuji
Kobayashi, Masahiro
Kumada, Hiromitsu
Kaneko, Shuichi
Pracht, Marc
Mamontov, Konstantin
Meyer, Tim
Mody, Kalgi
Kubota, Tomoki
Dutcus, Corina E.
Saito, Kenichi
Siegel, Abby B.
Dubrovsky, Leonid
Llovet, Josep M.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[9] SAFETY AND EFFICACY OF LENVATINIB PLUS REDUCED PEMBROLIZUMAB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA
Wu, Chi-Jung
Hung, Ya-Wen
Lee, Pei-Chang
Lee, Chieh-Ju
Hou, Ming-Chih
Huang, Yi-Hsiang
HEPATOLOGY, 2020, 72 : 705A - 705A
[10] Lenvatinib plus pembrolizumab versus lenvatinib in patients with unresectable hepatocellular carcinoma: A real world study.
Lee, I-Cheng
Wu, Chi-Jung
Chen, San-Chi
Chao, Yee
Huang, Yi-Hsiang
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →